To view a copy of this licence, visit About this article Cite this article Miljkovic, J.L., Burger, N., Yu, C.S
2021;106(2):E592-601
Despite reasonably successful progress in clinical trials of its most advanced oral candidate danuglipron, the company halted development in April, owing to a possible drug-induced liver injury in one participant of an earlier study
starting doses of Wegovy and Zepbound would cost Medicaid programs $350/month Duration : five-year model, concluding December 2031 Lifestyle support : all enrollees receiving GLP-1s for weight management must receive access to a lifestyle support program provided by the manufacturer at no cost Prior authorization : still required
Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Murai M